Go Deep
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,173 | 148.1 | 1.68 | 0.67 | 5,292.56 |
| Oct 2026 | 20,117 | 149.7 | 1.70 | 0.67 | 5,303.07 |
| Oct 2026 | 20,539 | 147.0 | 1.67 | 0.67 | 5,178.81 |
| Oct 2026 | 20,471 | 149.0 | 1.69 | 0.67 | 5,235.40 |
| Oct 2026 | 20,391 | 151.5 | 1.72 | 0.67 | 5,322.57 |
| Oct 2026 | 20,512 | 147.8 | 1.67 | 0.67 | 5,179.01 |
| Oct 2026 | 20,513 | 147.8 | 1.67 | 0.67 | 5,183.61 |
| Oct 2026 | 20,356 | 152.5 | 1.73 | 0.67 | 5,351.44 |
| Oct 2026 | 20,465 | 149.2 | 1.69 | 0.67 | 5,221.88 |
| Oct 2026 | 20,340 | 153.1 | 1.73 | 0.67 | 5,345.35 |
BioMarin Pharmaceutical Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 989,708,000.0 | 766,208,000.0 | 874,565,000.0 | 776,133,000.0 |
| Net Profit | 44,762,000.0 | 105,527,000.0 | -46,573,000.0 | -30,744,000.0 |
| EPS | 0.2 | 0.6 | -0.2 | -0.2 |
BioMarin Pharmaceutical Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 3,221,253,000.0 | 2,853,915,000.0 | 2,419,226,000.0 | 2,096,039,000.0 | — |
| Net Profit | 348,901,000.0 | 426,859,000.0 | 167,645,000.0 | 141,561,000.0 | — |
| EPS | 1.8 | 2.2 | 0.9 | 0.8 | — |
BioMarin Pharmaceutical Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 7,594,022,000.0 | 6,988,940,000.0 | 6,841,603,000.0 | 6,375,074,000.0 | — |
| Total Liabilities | 1,507,023,000.0 | 1,330,950,000.0 | 1,890,054,000.0 | 1,771,918,000.0 | — |
| Total Equity | 6,086,999,000.0 | 5,657,990,000.0 | 4,951,549,000.0 | 4,603,156,000.0 | — |
Owes vs Owns
BioMarin Pharmaceutical Inc. owed $0.46 for every $1 it owned in Jun 2026, up from $0.28 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.46× | 0.20× | 0.19× | 0.28× | 0.28× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
BioMarin Pharmaceutical Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 20.6%Receivables 12.0%Inventory 17.1%Fixed assets (tangible) 12.5%Intangible assets 5.4%Long-term investments 6.5%Other assets 26.0%
How it's funded — Dec 2025
Long-term debt 7.9%Payables 4.1%Other liabilities 7.7%Shareholders' equity 80.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,560.6 | 1,137.7 | 1,073.8 | 1,291.5 |
| Receivables | 908.2 | 660.5 | 633.7 | 461.3 |
| Inventory | 1,298.9 | 1,232.7 | 1,107.2 | 894.1 |
| Fixed assets (tangible) | 952.5 | 1,043.0 | 1,066.1 | 1,073.4 |
| Intangible assets | 410.0 | 451.5 | 490.9 | 534.8 |
| Long-term investments | 492.2 | 521.2 | 611.1 | 333.8 |
| Other assets | 1,971.5 | 1,942.3 | 1,858.7 | 1,786.2 |
| Liabilities & equity | ||||
| Short-term debt | 8.7 | 7.6 | 493.9 | 10.4 |
| Long-term debt | 597.2 | 595.1 | 593.1 | 1,083.0 |
| Payables | 312.8 | 235.4 | 315.5 | 231.2 |
| Other liabilities | 588.4 | 492.8 | 487.6 | 447.3 |
| Shareholders' equity | 6,087.0 | 5,658.0 | 4,951.5 | 4,603.2 |
| Net tangible assets | 5,677.0 | 5,206.5 | 4,460.6 | 4,068.4 |
BioMarin Pharmaceutical Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 827,994,000.0 | 572,841,000.0 | 159,259,000.0 | 175,902,000.0 | — |
| Investing Activities | -414,242,000.0 | 136,491,000.0 | -111,244,000.0 | -20,029,000.0 | — |
| Financing Activities | -42,394,000.0 | -526,447,000.0 | -18,727,000.0 | -18,650,000.0 | — |